Abstract: Evaluation of Paxalisib in GBM AGILE, a Phase 3 Registration Platform Trial for Newly Diagnosed and Recurrent Glioblastoma
NOVEMBER 11, 2024
Neuro-Oncology – Society of Neuro-Oncology Annual Meeting
Abstract: Update on GBM AGILE: A Global, Phase 2/3 Adaptive Platform Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NOVEMBER 11, 2024
Neuro-Oncology – Society of Neuro-Oncology Annual Meeting
Abstract (EANO 2024, encore): Evaluation of VAL-083 in GBM AGILE, a Phase 3 Registration Platform Trial for Newly Diagnosed and Recurrent Glioblastoma
OCTOBER 17, 2024
Neuro-Oncology – European Association of Neuro-Oncology Annual Meeting
Abstract (EANO 2024, encore): GBM AGILE Platform Trial for Newly Diagnosed and Recurrent GBM: Results of First Experimental Arm, Regorafenib
OCTOBER 17, 2024
Neuro-Oncology – European Association of Neuro-Oncology Annual Meeting
Abstract: Global Expansion of GBM AGILE: A Phase II/III Adaptive Platform Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
OCTOBER 17, 2024
Neuro-Oncology – European Association of Neuro-Oncology Annual Meeting
Abstract: Update on GBM AGILE: A Global, Phase II/III Adaptive Platform Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
SEPTEMBER 2024
Annals of Oncology – European Society for Medical Oncology Annual Meeting
Abstract: Evaluation of VAL-083 in GBM AGILE, a Phase 3 Registration Platform Trial for Newly Diagnosed and Recurrent Glioblastoma
MAY 29, 2024
Journal of Clinical Oncology – American Society of Clinical Oncology Annual Meeting
Abstract: GBM AGILE Platform Trial for Newly Diagnosed and Recurrent GBM: Results of First Experimental Arm, Regorafenib
NOVEMBER 10, 2023
Neuro-Oncology – Society of Neuro-Oncology Annual Meeting
Abstract: Update on GBM AGILE: A Global, Phase 2/3 Adaptive Platform Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
SEPTEMBER 8, 2023
Neuro-Oncology – European Association of Neuro-Oncology Annual Meeting
Abstract: GBM AGILE: A Global, Phase 2/3 Adaptive Platform Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
APRIL 14, 2023
Cancer Research – American Association for Cancer Research Annual Meeting
Automatic Population of the Case Report Forms for an International Multifactorial Adaptive Platform Trial Amid the COVID-19 Pandemic
MAY 31, 2024
AMIA JT SUMMITS TRANSL SCI PROC.
Simvastatin in Critically Ill Patients with Covid-19
OCTOBER 25, 2023
NEJM
Continuation of therapeutic dose heparin for critically ill patients with COVID-19
MAY 31, 2023
SPRINGERLINK
Adaptive Platform Trials: The Clinical Trial of the Future? (C)
JULY 2021
ARIEL D. STERN AND SARAH MEHTA, HARVARD BUSINESS REVIEW
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
FEBRUARY 25, 2021
NEJM
Adaptive Platform Trials: The Clinical Trial of the Future? (B)
SEPTEMBER 2019
ARIEL D. STERN AND SARAH MEHTA, HARVARD BUSINESS REVIEW
Adaptive Platform Trials: Definition, Design, Conduct and Reporting Considerations
AUGUST 28, 2019
NATURE REVIEWS DRUG DISCOVERY
Adaptive Platform Trials: The Clinical Trial of the Future?
SEPTEMBER 26, 2017
ARIEL D. STERN AND SARAH MEHTA, HARVARD BUSINESS REVIEW
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
SEPTEMBER 20, 2017
DR. BRIAN M. ALEXANDER, DR. SUJUAN BA, DR. WEBSTER CAVENEE, DR. TIMOTHY F. CLOUGHESY, DR. W.K. ALFRED YUNG – AMERICAN ASSOCIATION FOR CANCER RESEARCH
